The US Food and Drug Administration (FDA) approved PD-1 checkpoint inhibitors (nivolumab and pembrolizumab) for use in non-small cell lung cancer and melanoma at the end of 2014, ushering in a new era of immunotherapy research for HCC. Here, PDCD1 is linked to melanoma.